title: [Current status and future direction of the treatment of CRPC (castration resistant prostate cancer)].
abstract: A new era of the treatment of prostate cancer has now come in Japan with the approval of several new agents for castration resistant prostate cancer (CRPC), which were delayed by 2-3 years compared to their introduction in Westerns. In addition to those development of new agents, a good news was presented in ASCO 2014 that is a successful phase III trial of chemo-hormonal therapy for hormone naïve (responsive) metastatic prostate cancer (HRPC). We must establish a reasonable treatment strategy for the advanced and high risk prostate cancer.
authors.forename: Hideyuki
authors.initials: H
authors.lastname: Akaza
mesh_terms: D017677:Age Distribution; D000726:Androgen Antagonists / Q000627:therapeutic use; D018450:Disease Progression; D015195:Drug Design; D006801:Humans; D008297:Male; D064129:Prostatic Neoplasms, Castration-Resistant / Q000453:epidemiology / Q000628:therapy*; D016896:Treatment Outcome
chemical_list: D000726:Androgen Antagonists